[go: up one dir, main page]

AU1991097A - Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases - Google Patents

Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases

Info

Publication number
AU1991097A
AU1991097A AU19910/97A AU1991097A AU1991097A AU 1991097 A AU1991097 A AU 1991097A AU 19910/97 A AU19910/97 A AU 19910/97A AU 1991097 A AU1991097 A AU 1991097A AU 1991097 A AU1991097 A AU 1991097A
Authority
AU
Australia
Prior art keywords
cross
dialdehydes
augmenting
linkers
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19910/97A
Inventor
Avi Eisenthal
Cohava Gelber
Amnon Gonenne
Meir Shinitzky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMMUNOTHERAPY Inc
Yeda Research and Development Co Ltd
Original Assignee
IMMUNOTHERAPY Inc
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IMMUNOTHERAPY Inc, Yeda Research and Development Co Ltd filed Critical IMMUNOTHERAPY Inc
Publication of AU1991097A publication Critical patent/AU1991097A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU19910/97A 1996-03-15 1997-03-13 Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases Abandoned AU1991097A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61683496A 1996-03-15 1996-03-15
US08616834 1996-03-15
US80376497A 1997-02-21 1997-02-21
US08803764 1997-02-21
PCT/US1997/003916 WO1997033612A1 (en) 1996-03-15 1997-03-13 Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-link treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases

Publications (1)

Publication Number Publication Date
AU1991097A true AU1991097A (en) 1997-10-01

Family

ID=27087880

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19910/97A Abandoned AU1991097A (en) 1996-03-15 1997-03-13 Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases

Country Status (2)

Country Link
AU (1) AU1991097A (en)
WO (1) WO1997033612A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043655A1 (en) * 1997-04-02 1998-10-08 Bioniche Inc. Use of bacterial cell wall extracts for treating topical disorders and wounds
MXPA00003108A (en) 1997-10-03 2001-07-01 Polysaccharidos immunization trainers, preparation of them, and use as adjuvants and immunoestimulan
WO1999055715A2 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
CA2395493C (en) 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
AU2002249917A1 (en) 2001-01-04 2002-08-12 Yale University Induction of immune responses to isoaspartyl-modified antigens
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
WO2003051907A2 (en) * 2001-12-18 2003-06-26 Health Research, Inc. Method of enhancing immunogenicity by covalent linkage of antigens to proteins on the surface of dendritic cells
EP2073011A1 (en) * 2007-12-20 2009-06-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods of processing biological samples
BRPI0800357A2 (en) * 2008-03-10 2009-10-27 Fundacao Oswaldo Cruz method for producing a stabilized vaccine
ITTO20110652A1 (en) * 2011-07-20 2013-01-21 Medestea Res & Production S P A COMPOUND DERIVED FROM THE ADENINE HAVING IMMUNO-MODULATING ACTION, ANTI-INFLAMMATORY AND ANTI-DOLUTION ACTION
WO2022017217A1 (en) * 2020-07-24 2022-01-27 四川大学华西医院 Ebv-targeted allogeneic b cell vaccine and preparation method therefor
CN116392585A (en) * 2023-04-06 2023-07-07 中山大学孙逸仙纪念医院 A kind of tumor vaccine adjuvant and its application
CN119455125A (en) * 2024-11-18 2025-02-18 华中科技大学同济医学院附属协和医院 Heart valve modification method, artificial heart valve and application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0615758B1 (en) * 1988-05-24 1999-09-22 Yeda Research And Development Co. Ltd. Anti-tumor vaccines
AU4977896A (en) * 1995-02-17 1996-09-04 Immunotherapy, Inc. Immunotherapy screening, prognosis, and treatment methods and compositions

Also Published As

Publication number Publication date
WO1997033612A1 (en) 1997-09-18

Similar Documents

Publication Publication Date Title
MY125202A (en) Vaccine
AU1991097A (en) Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
WO1999051259A3 (en) Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO2001034801A3 (en) Recombinant gelatin in vaccines
AU8483391A (en) Improved oligosaccharide conjugate vaccines
CA2223080A1 (en) Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2,5-anhydro-d-mannose terminal structure and conjugate vaccine thereof
PT1104306E (en) CPG COMPOSITIONS AND SAPONIN ADJUVANTS AND THEIR METHODS
EP2022800A3 (en) Compositions for the therapy and diagnosis of ovarian cancer
PL351893A1 (en) Vaccines
HK1043943A1 (en) Streptococcus pneumoniae proteins and vaccines
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
AU2238597A (en) Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen
MX9707944A (en) Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them.
AU8113591A (en) Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties
AU2917697A (en) Dendritic cell receptor
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
AU6921300A (en) Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
EP1820514A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
HUP9802419A3 (en) Antigenic preparations, process for preparation and uses thereof
ZA971403B (en) Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof.
WO1997011669A3 (en) MHC-class II restricted melanoma antigens and their use in therapeutic methods
WO2000012122A3 (en) Low-molecular fragments of hyaluronic acid for the preparation of vaccines
CA2249390A1 (en) Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor